-- Piramal Pharma（NSE：PPLPHARMA，BOM：543635）公佈，截至3月31日的第四財季，公司合併淨虧損8,820萬印度盧比，而去年同期獲利15.4億盧比。 該公司週二向印度證券交易所提交的文件顯示，第四財季每股虧損0.07盧比，去年同期每股收益為1.16盧比。 第四財季營業收入為275億盧比，與去年同期大致持平。 該公司股價在近期交易中下跌近1%。
Related Articles
Asia
Willfar Information Technology's Q1 2026 Profit Rises 6%
Willfar Information Technology (SHA:688100), a 59.55%-owned subsidiary of Wasion Holdings (HKG:3393), reported 148.3 million yuan in attributable profit for the first quarter of 2026, up 6.4% from 139.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Revenue fell 4.2% year on year to 531.9 million yuan, figures showed.
$HKG:3393$SHA:688100
Asia
Zhongjin Gold's 2025 Profit Jumps 46%
Zhongjin Gold's (SHA:600489) attributable profit rose 46% to 4.93 billion yuan in 2025 from 3.39 billion yuan in 2024, according to a Wednesday filing with the Shanghai bourse.Earnings per share at the non-ferrous metals miner increased to 1.02 yuan from 0.70 yuan in the previous year.Operating revenue grew 21% year over year to 79.1 billion yuan from 65.6 billion yuan.
$SHA:600489
Asia
Jinduicheng Molybdenum's Q1 Profit Jumps 33%, Revenue Rises 27%
Jinduicheng Molybdenum's (SHA:601958) net profit attributable to shareholders in the first quarter jumped 33% year on year to 901.6 million yuan, or 0.279 yuan per share, according to a Wednesday disclosure on Shanghai filing.The attributable profit a year earlier was almost 678 million yuan, or 0.210 yuan per share.Operating revenue rose 27% to 4.16 billion yuan from 3.28 billion yuan in the previous year.The Chinese molybdenum miner's shares jumped less than 7% at the close.
$SHA:601958